OUR PORTFOLIO
OUR COMPANIES REDEFINE THE THERAPEUTICS OF TOMORROW
CARMINE THERAPEUTICS
Carmine Therapeutics is an Esco Ventures X company pioneering a powerful new class of genetic medicines based on engineered red blood cells extracellular vesicles (RBCEVs), founded in 2019 by Esco Ventures and Professors Harvey Lodish, Minh Le and Jiahai Shi.
PAIRX BIO
PairX Bio Pte Ltd is developing next generation cancer immunotherapies targeting shared tumor-associated antigens derived from aberrantly spliced proteins. The foundational technology was developed at Duke-NUS Medical School in Prof. David Epstein’s lab.
HUMMINGBIRD BIOSCIENCE
Hummingbird Bioscience focuses on the discovery and early development of oncology drugs, from pre-clinical target validation to proof-of-concept (Phase II Clinical Trials).
EVX07
To be disclosed
EVX08
To be disclosed